CASR and ovarian carcinoma: A recent study performed by Li T et al. (2021), focusing on exosomal hsa-miR-429 in ovarian cancer, showed that this specific miRNA molecule confers resistance to cisplatin via CASR/STAT3 pathway regulation [69].